Thousand Oaks Biopharmaceuticals has secured 1.5 billion yuan ($236.1 million) in a new funding round led by Chinese investors as the contract development & manufacturing organisation (CDMO) looks to develop new technologies and expand operations.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
